GILD Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of 23.56% compared to Gilead Sciences's net margin of 15.24%. Gilead Sciences's return on equity of 2.5% beat Johnson & Johnson's return on equity of 19.98%.

Gilead Sciences has a consensus price target of $111.26, signalling downside risk potential of -0.16%. On the other hand Johnson & Johnson has an analysts' consensus of $169.07 which suggests that it could grow by 3.84%. Given that Johnson & Johnson has higher upside potential than Gilead Sciences, analysts believe Johnson & Johnson is more attractive than Gilead Sciences.

Gilead Sciences has a beta of 0.213, which suggesting that the stock is 78.702% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.473, suggesting its less volatile than the S&P 500 by 52.686%.

Gilead Sciences has a quarterly dividend of $0.79 per share corresponding to a yield of 2.78%. Johnson & Johnson offers a yield of 3.05% to investors and pays a quarterly dividend of $1.24 per share. Gilead Sciences pays 816.25% of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Gilead Sciences's is not.

Gilead Sciences quarterly revenues are $7.6B, which are smaller than Johnson & Johnson quarterly revenues of $22.5B. Gilead Sciences's net income of $1.8B is lower than Johnson & Johnson's net income of $3.4B. Notably, Gilead Sciences's price-to-earnings ratio is 301.19x while Johnson & Johnson's PE ratio is 28.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Gilead Sciences is 4.87x versus 4.45x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 23.56% compared to Gilead Sciences's net margin of 32.59%. Gilead Sciences's return on equity of 2.5% beat Eli Lilly and's return on equity of 80.24%.

Gilead Sciences has a consensus price target of $111.26, signalling downside risk potential of -0.16%. On the other hand Eli Lilly and has an analysts' consensus of $1,006.63 which suggests that it could grow by 23.74%. Given that Eli Lilly and has higher upside potential than Gilead Sciences, analysts believe Eli Lilly and is more attractive than Gilead Sciences.

Gilead Sciences has a beta of 0.213, which suggesting that the stock is 78.702% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.817%.

Gilead Sciences has a quarterly dividend of $0.79 per share corresponding to a yield of 2.78%. Eli Lilly and offers a yield of 0.66% to investors and pays a quarterly dividend of $1.50 per share. Gilead Sciences pays 816.25% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Gilead Sciences's is not.

Gilead Sciences quarterly revenues are $7.6B, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Gilead Sciences's net income of $1.8B is lower than Eli Lilly and's net income of $4.4B. Notably, Gilead Sciences's price-to-earnings ratio is 301.19x while Eli Lilly and's PE ratio is 69.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Gilead Sciences is 4.87x versus 16.33x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 23.56% compared to Gilead Sciences's net margin of -117.16%. Gilead Sciences's return on equity of 2.5% beat Moderna's return on equity of -29.09%.

Gilead Sciences has a consensus price target of $111.26, signalling downside risk potential of -0.16%. On the other hand Moderna has an analysts' consensus of $54.40 which suggests that it could grow by 57.13%. Given that Moderna has higher upside potential than Gilead Sciences, analysts believe Moderna is more attractive than Gilead Sciences.

Gilead Sciences has a beta of 0.213, which suggesting that the stock is 78.702% less volatile than S&P 500. In comparison Moderna has a beta of 1.863, suggesting its more volatile than the S&P 500 by 86.269%.

Gilead Sciences has a quarterly dividend of $0.79 per share corresponding to a yield of 2.78%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Gilead Sciences pays 816.25% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Gilead Sciences quarterly revenues are $7.6B, which are larger than Moderna quarterly revenues of $956M. Gilead Sciences's net income of $1.8B is higher than Moderna's net income of -$1.1B. Notably, Gilead Sciences's price-to-earnings ratio is 301.19x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Gilead Sciences is 4.87x versus 4.20x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of 23.56% compared to Gilead Sciences's net margin of 31.35%. Gilead Sciences's return on equity of 2.5% beat Vertex Pharmaceuticals's return on equity of -3.23%.

Gilead Sciences has a consensus price target of $111.26, signalling downside risk potential of -0.16%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $496.78 which suggests that it could fall by -1.58%. Given that Vertex Pharmaceuticals has more downside risk than Gilead Sciences, analysts believe Gilead Sciences is more attractive than Vertex Pharmaceuticals.

Gilead Sciences has a beta of 0.213, which suggesting that the stock is 78.702% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.414, suggesting its less volatile than the S&P 500 by 58.629%.

Gilead Sciences has a quarterly dividend of $0.79 per share corresponding to a yield of 2.78%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Gilead Sciences pays 816.25% of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Gilead Sciences quarterly revenues are $7.6B, which are larger than Vertex Pharmaceuticals quarterly revenues of $2.9B. Gilead Sciences's net income of $1.8B is higher than Vertex Pharmaceuticals's net income of $913M. Notably, Gilead Sciences's price-to-earnings ratio is 301.19x while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Gilead Sciences is 4.87x versus 11.88x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.